Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Alzheimer disease

Lecanemab trial in AD brings hope but requires greater clarity

Nature Reviews Neurology (2023)Cite this article

Subjects

The phase III Clarity AD clinical trial of lecanemab, an amyloid-targeting antibody, showed a small clinical benefit in people with Alzheimer disease. However, several questions remain regarding the true clinical relevance, safety and accessibility of lecanemab in this patient population.

Refers to van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2212948 (2022).

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2212948 (2022).

    Article  Google Scholar 

  2. Ackley, S. F. et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ 372, n156 (2021).

    Article  Google Scholar 

  3. Gleason, A., Ayton, S. & Bush, A. I. Unblinded by the light: amyloid-related imaging abnormalities in Alzheimer’s clinical trials. Eur. J. Neurol. 28, e1 (2021).

    Article  CAS  Google Scholar 

  4. Center for Drug Evaluation and Research. Aduhelm (aducanumab) FDA statistical review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000StatR.pdf (2021).

  5. Andrews, J. S. et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement. (N.Y.) 5, 354–363 (2019).

    Article  Google Scholar 

  6. Lansdall, C. J. et al. Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer’s disease. J. Prev. Alzheimers Dis. https://doi.org/10.14283/jpad.2022.102 (2022).

    Article  Google Scholar 

  7. Piller, C. Second death linked to potential antibody treatment for Alzheimer’s disease. Science https://doi.org/10.1126/science.adf9701 (2022).

    Article  Google Scholar 

  8. Nestor, S. M. et al. Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database. Brain 131, 2443–2454 (2008).

    Article  Google Scholar 

  9. Silbert, L. C. et al. Changes in premorbid brain volume predict Alzheimer’s disease pathology. Neurology 61, 487–492 (2003).

    Article  CAS  Google Scholar 

  10. Canevelli, M. et al. “Real world” eligibility for aducanumab. J. Am. Geriatr. Soc. 69, 2995–2998 (2021).

    Article  Google Scholar 

Download references

Acknowledgements

M.T. is a full-time employee at the intramural programme of the National Institute on Aging (Baltimore, MD, USA). R.H. is supported by the National Institute for Health Research University College Hospital London Biomedical Research Centre (London, UK).

Author information

Authors and Affiliations

  1. Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD, USA

    Madhav Thambisetty

  2. Division of Psychiatry, University College London, London, UK

    Robert Howard

Authors
  1. Madhav Thambisetty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Howard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Madhav Thambisetty.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Thambisetty, M., Howard, R. Lecanemab trial in AD brings hope but requires greater clarity. Nat Rev Neurol (2023). https://doi.org/10.1038/s41582-022-00768-w

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41582-022-00768-w

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing